Quo vadis motor neuron disease?
- PMID: 27019797
- PMCID: PMC4804252
- DOI: 10.5662/wjm.v6.i1.56
Quo vadis motor neuron disease?
Abstract
Motor neuron disease (MND), also known as amyotrophic lateral sclerosis, is a relentlessly progressive neurodegenerative condition that is invariably fatal, usually within 3 to 5 years of diagnosis. The aetio-pathogenesis of MND remains unresolved and no effective treatments exist. The only Food and Drug Administration approved disease modifying therapy is riluzole, a glutamate antagonist, which prolongs survival by up to 3 mo. Current management is largely symptomatic/supportive. There is therefore a desperate and unmet clinical need for discovery of disease mechanisms to guide novel therapeutic strategy. In this review, we start by introducing the organizational anatomy of the motor system, before providing a clinical overview of its dysfunction specifically in MND. We then summarize insights gained from pathological, genetic and animal models and conclude by speculating on optimal strategies to drive the step change in discovery, which is so desperately needed in this arena.
Keywords: Amyotrophic lateral sclerosis; Disease models; Motor neuron disease; Neurodegeneration.
Figures
Similar articles
-
Harnessing cellular aging in human stem cell models of amyotrophic lateral sclerosis.Aging Cell. 2019 Feb;18(1):e12862. doi: 10.1111/acel.12862. Epub 2018 Dec 19. Aging Cell. 2019. PMID: 30565851 Free PMC article. Review.
-
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):191-206. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003. PMID: 13129806 Review.
-
Estimating Amyotrophic Lateral Sclerosis and Motor Neuron Disease Prevalence in Portugal Using a Pharmaco-Epidemiological Approach and a Bayesian Multiparameter Evidence Synthesis Model.Neuroepidemiology. 2019;53(1-2):73-83. doi: 10.1159/000499485. Epub 2019 May 22. Neuroepidemiology. 2019. PMID: 31117082
-
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).Cochrane Database Syst Rev. 2002;(2):CD001447. doi: 10.1002/14651858.CD001447. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001447. doi: 10.1002/14651858.CD001447.pub2 PMID: 12076411 Updated. Review.
-
Epidemiological characteristics of motor neuron disease in Chinese patients.Acta Neurol Scand. 2014 Aug;130(2):111-7. doi: 10.1111/ane.12240. Epub 2014 Apr 1. Acta Neurol Scand. 2014. PMID: 24689740
Cited by
-
Neurodegenerative Diseases: Might Citrus Flavonoids Play a Protective Role?Molecules. 2016 Sep 30;21(10):1312. doi: 10.3390/molecules21101312. Molecules. 2016. PMID: 27706034 Free PMC article. Review.
-
Decoding the relationship between ageing and amyotrophic lateral sclerosis: a cellular perspective.Brain. 2020 Apr 1;143(4):1057-1072. doi: 10.1093/brain/awz360. Brain. 2020. PMID: 31851317 Free PMC article. Review.
-
Retinal correlates of neurological disorders.Ther Adv Chronic Dis. 2019 Dec 2;10:2040622319882205. doi: 10.1177/2040622319882205. eCollection 2019. Ther Adv Chronic Dis. 2019. PMID: 31832125 Free PMC article. Review.
-
Human Stem Cell-Derived Astrocytes: Specification and Relevance for Neurological Disorders.Curr Stem Cell Rep. 2016;2(3):236-247. doi: 10.1007/s40778-016-0049-1. Epub 2016 Jun 3. Curr Stem Cell Rep. 2016. PMID: 27547709 Free PMC article. Review.
References
-
- Kuffler SW, Hunt CC, Quilliam JP. Function of medullated small-nerve fibers in mammalian ventral roots; efferent muscle spindle innervation. J Neurophysiol. 1951;14:29–54. - PubMed
-
- Burke RE, Strick PL, Kanda K, Kim CC, Walmsley B. Anatomy of medial gastrocnemius and soleus motor nuclei in cat spinal cord. J Neurophysiol. 1977;40:667–680. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources